Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

Roughly Half of Patients Don’t Have Symptoms Prior to a First MI

News Daily News

Roughly Half of Patients Don’t Have Symptoms Prior to a First MI

July 09, 2025

LDL Control Remains Poor in CAD Patients: NHANES

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

News Daily News

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

July 08, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

New STRENGTH Analysis Revives Omega-3 Debate

News Conference News ACC 2021

New STRENGTH Analysis Revives Omega-3 Debate

May 20, 2021

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

More Circulating Omega-3s May Boost Prognosis After STEMI

News Daily News

More Circulating Omega-3s May Boost Prognosis After STEMI

October 26, 2020

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

News Daily News

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

August 31, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

November 10, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.